Brentuximab Vedotin and Imatinib in Patients With Relapsed or Refractory ALK+ ALCL
Status:
Active, not recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
This is an open label pilot study of combining BV in a licensed indication with imatinib in
patients with ALCL. It is intended as a "window of opportunity" trial in which the study
drugs will be given as an initial substitute for conventional chemotherapy with the intention
to achieve a remission enabling the patients to proceed to autologous or allogeneic stem cell
transplantation, if eligible.